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Purpose: To investigate the antimicrobial resistance rate of 110 E. coli strains, isolated from UTIs in 
Etlik Lokman Hekim Hospital, Etlik, Ankara, Turkey.  
Methods: API-20E System (bioMerieux, France) was used to identify E. coli isolates. Antimicrobial 
susceptibility testing was conducted on Mueller-Hinton Agar plates (Merck, Germany) using agar disc 
diffusion method and the results were expressed as susceptible or resistant according to the criteria 
recommended by the Clinical and Laboratory Standarts Institute (CLSI).  
Results: The resistance rates detected were 56 % to ampicillin, 24 % to ampicillin sulbactam, 9 % to 
gentamicin, 15 % to ciprofloxacin, 36 % to trimethoprim sulfamethoxazole, 12 % to cefazolin, and 7 % to 
cefuroxime. All isolates tested were susceptible to fosfomycin and nitrofurantoin.  
Conclusion: When the high resistance rates in Turkey are taken into consideration, antimicrobial agent 
usage policies and empirical therapies should be based on antimicrobial resistance surveillance studies.  
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INTRODUCTION 
 
The increasing prevalence of antibiotic 
resistance is a major health problem 
worldwide. The World Health Organization 
(WHO) and the European Commision (EC) 
have recognized the importance of studying 
the emergence and determinants of 
resistance and the need for strategies for its 
control [1]. 
 
Urinary tract infection (UTI) is a common 
community-acquired bacterial disease which 
frequently affects female outpatients. 
Escherichia coli, the most common member 
of the family Enterobacteriaceae, accounts 
for 75 - 90 % of all UTIs in both inpatients 
and outpatients [2]. Increasing rates of 
resistance among bacterial uropathogens has 
caused growing concern in both developed 
and developing countries. A rise in bacterial 
resistance to antibiotics complicates 
treatment of infections. In general, up to 95 % 
of cases with severe symptoms are treated 
without bacteriological investigation. Also, 
appropriate antibiotic treatment may vary 
according to the patient’s age, sex and the 
infecting agent [2,3]. 
  
In this study, the objective was to investigate 
the antimicrobial resistance rates of 110 E. 
coli strains, isolated from the urine cultures of 
patients with UTI in Etlik Lokman Hekim 






A total of 110 E.coli strains isolated from 
urine cultures processed between September 
2008 and April 2009 in Etlik Lokman Hekim 
Hospital, Etlik, Ankara, Turkey were included 
in the study. Identification of bacterial strain 
was performed by classical identification 





Antimicrobial susceptibility testing 
 
Antimicrobial susceptibility testing was 
conducted on Mueller Hinton Agar (MHA) 
plates (Merck, Germany) by agar disc 
diffusion method. Each strain was inoculated 
in Mueller Hinton Broth (Merck, Germany), 
and after 24 h of incubation at 37 ºC, they 
were streaked using sterile swabs on MHA 
plates. The plates were kept at room 
temperature for 10 min and then the standard 
antimicrobial discs were placed on the 
inoculated MHA plates and incubated for 24 h 
at 37 ºC.  The following standard 
antimicrobial discs were tested: ampicillin, 
ampicillin sulbactam, gentamicin, 
ciprofloxacin, nitrofurantoin, trimethoprim 
sulfamethoxazole, cefazolin, fosfomycin and 
cefuroxime. The results were expressed as 
susceptible or resistant according to the 




Statistical analysis for probability was carried 
out with Minitab 14.0 program that 
incorporates 2P application [Minitab Inc., 
USA]. Z-Test was employed to determine the 
existence of significant differences between 
data (p ≤ 0.05). 
 
RESULTS   
 
Resistance of urinary isolates to 
antimicrobials is shown in Tables 1 and 2. 
The resistance rates detected were 56% to 
ampicillin, 24% to ampicillin sulbactam, 9% to 
gentamicin, 15% to ciprofloxacin, 36% to 
trimethoprim sulfamethoxazole, 12% to 
cefazolin, 7% to cefuroxime. All isolates 
tested were susceptible to fosfomycin and 
nitrofurantoin. The difference observed 
between the resistance to ampicillin and 
trimethoprim/sulfamethoxazole were statistic-
cally significant (p ≤ 0.05) but there was no 
statistically significant difference in resistance 
between the following: ampicillin sulbactam/ 
ciprofloxacin and cefazolin; ciprofloxacin/ 
cefazolin, gentamicin and cefuroxime; 
cefazolin/gentamicin and cefuroxime;  
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Table 1: Resistance of urinary E.coli isolates to antimicrobials (%). 
 
Bacteria AMP SAM GM CIP TMP-SXT CZ CXM FOS NIT 
E. coli 56 24 9 15 36 12 7 0 0 
 
AMP = ampicillin;   SAM = ampicillin sulbactam;  GM = gentamicin;  CIP = ciprofloxacin;  FOS = 
fosfomycin; TMP-SXT = trimethoprim sulfametoxazole; CZ = cefazolin; CXM = cefuroxime;   NIT = 
nitrofurantoin 
 
Table 2: Resistance of urinary E.coli isolates to antimicrobials in Turkey (%) 
 
Rate of resistance (%) 
Studies 
AMP   SAM  GM    CIP TMP-
SXT 
CZ CXM FOS   NIT 
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AMP = ampicillin;   SAM = ampicillin sulbactam;  GM = gentamicin;  CIP = ciprofloxacin;  FOS = 
fosfomycin; TMP-SXT = trimethoprim sulfametoxazole; CZ = cefazolin; CXM = cefuroxime; NIT = 
nitrofurantoin; - = unapplied in the study 
 
   Table 3: p values of antimicrobials (p ≤ 0,05 values are significant) 
 
     TMP- 
SXT 
SAM CIP CZ GM CXM NIT FOS 
AMP 0.002 0.001 0.000 0.000 0.000 0.000 0.000 0.000 
TMP-SXT  0.038 0.000 0.000 0.000 0.000 0.000 0.000 
SAM   0.124 0.020 0.003 0.001 0.000 0.000 
CIP    0.431 0.148 0.054 0.000 0.000 
CZ     0.508 0.250 0.000 0.000 
GM      0.623 0.001 0.001 
CXM       0.007 0.007 
NIT        1.000 
AMP = ampicillin;   SAM = ampicillin sulbactam;  GM = gentamicin;  CIP = ciprofloxacin;  FOS = 
fosfomycin; TMP-SXT = trimethoprim sulfametoxazole; CZ = cefazolin; CXM = cefuroxime; NIT = 
nitrofurantoin
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gentamicin/cefuroxime, cefuroxime/fosfomy-
cin, nitrofurantoin and nitrofurantoin/ 




The antimicrobial resistance of bacteria is a 
problem of global concern. There is a 
correlation between antibiotic use and 
subsequent resistance [5]. Antibacterial 
consumption is increasing in many countries 
around the world, and it is increasingly 
recognized as the main reason for the 
emergence of resistance [6]. 
 
The majority of UTIs are treated empirically 
especially in developing countries where 
patients often can not afford to consult a 
physician or to conduct laboratory analysis 
[2].
 
The high prevalence of antimicrobial 
resistance among UTI E. coli isolates 
emphasizes the necessity to review empirical 
therapies [7].
 
Empirical therapy should be 
based on local antimicrobial resistance 
monitoring in order to prevent increase in 
resistance to drugs used in the treatment of 
UTIs [8]. A North American UTI Collaborative 
Alliance study determined the susceptibility of 
antibiotics commonly used for the treatment 
of UTIs, to E. coli urinary isolates obtained 
from outpatients in various geographic 
regions in the USA and Canada. Overall, 
resistance to ampicillin was 37.7%, followed 
by trimethoprim/sulfamethoxazole 21.3%, 
nitrofurantoin 1.1% and ciprofloxacin 5.5% 
[9]. The resistance rates (except for 
nitrofurantoin) found in our study were higher 
than those in the North American study. 
 
In a study conducted in Senegal, the 
resistance rates reported were: 
trimethoprim/sulfamethoxazole 67.8%; and 
ampicillin 73.6% [2]. These resistance rates 
were higher than those obtained in the 
present work. The higher values found in 
these other studies can be explained by 
widespread, frequent and uncontrolled use of 
antimicrobials. 
 
The resistance rates found in studies 
performed in Turkey are given in Table 2. In 
one of them, Arıkan Akan [10], which 
compared resistance rates between 2001 
and 2002, the results indicate that empirical 
treatment should be avoided and that 
antimicrobial chemotherapy should be based 
on the result of in vitro antimicrobial 
susceptibility tests [10].  
 
The increasing resistance of ampicillin and 
trimethoprim sulfamethoxazole to E. coli has 
been reported in other studies from Turkey 
and other countries [15-19].
 
They were higher 
than the rates reported in our study. This 
could be attributed to the different 
antimicrobial agent use policies of the various 
centers involved in the studies, more frequent 
use of antimicrobials by the patients and 
easier access to antimicrobials without 
prescription. On the basis of our findings, 
antimicrobials such as ampicillin and 
trimethoprim/sulfamethoxazole should no 
longer be recommended for initial empirical 
therapies for UTIs. Furthermore, as result of 
the high resistance rates, trimethoprim/ 
sulfamethoxazole, ampicillin and ampicillin 
sulbactam do not seem to be appropriate for 
the empirical treatment of community-
acquired UTIs.  
 
Gentamicin, ciprofloxacin, cefazolin and 
cefuroxime may be considered as alternative 
therapies but before such a decision, the 
antimicrobial susceptibilities of the pathogens 
causing the UTIs should be investigated and 
necessary precautions taken against 
resistance development. Fosfomycin and 
nitrofurantoin were found to be the most 
effective antimicrobials. As a result, 
nitrofurantoin and fosfomycin are 
recommended for empirical therapy of UTIs. 
 
Since the susceptibility of uropathogenic 
E.coli strains to antimicrobials has been 
gradually increasing, it is imperative that prior 
to deciding on antimicrobial therapy, the 
antimicrobial susceptibilities of the pathogens 
causing the UTI should be investigated in 
order to minimise resistance development. 
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CONCLUSION 
 
It is hereby recommended that in view of the 
high resistance rates to antimicrobial agents 
used in UTI therapy in Turkey, antimicrobial 
agent usage policies, especially empirical 
therapies, should be based on antimicrobial 
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